Key facts
- Notable investors include Hoxton Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ephla Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ephla Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ephla Bio
Developer of targeted B-cell therapeutics designed to address immune-related conditions using machine learning. The company offers clinician and researcher-led development with cross-disciplinary expertise, enabling individuals with autoimmune disorders and later those with blood cancers, access to targeted treatment options.
- Sector
- Healthcare
- HQ
- VA
- Founded
- 2024
- Employees
- 6
- Website
- ephlabio.com/
- Ownership
- Privately Held (backing)
Ephla Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ephla Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ephla Bio in its N-PORT filings yet. We sweep new filings monthly.